GHRS

GH Research PLC

GHRS.US ghres.com
Healthcare · Biotechnology
27.28
-0.28 (-1.02%)
USD · NASDAQ
52-week range
12.04
31.44
Trading at 79% of the 52-week range
Market Cap
1.89B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
5.24
Div. Yield
N/A
% Institutions
71.36%
% Insiders
24.20%

1 Year

+111.6%

3 Year

+172.8%

10 Year

+41.7%
Description

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Company Information

▼
Company Name
GH Research PLC
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: IE000GID8VI0
CIK: 0001855129
Currency: USD
Full Time Employees: 73
Phone: 353 1 437 8334
Website: ghres.com
Fiscal Year End: December
IPO Date: Jun 25, 2021
Description:

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Address:

Joshua Dawson House, Dublin, Ireland, D02 RY95

People

▼

Directors & Officers

Name Title Year Born
Mr. Florian Schonharting M.Sc. (Econ) Co-Founder & Non-Executive Chairman of the Board 1969
Dr. Velichka Valcheva M.D., M.Sc. Chief Executive Officer 1975
Mr. Magnus Halle Co-Founder & MD of Ireland 1997
Ms. Julie Ryan F.C.A. Vice President of Finance 1986
Mr. Aaron Cameron M.B.A. Chief Operating Officer 1985

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bvf Inc 8.65M Mar 31, 2026 12.60% $3.87 -2.01%
RA Capital Management, LLC 7.68M Mar 31, 2026 11.18% $1.14 0.00%
RTW INVESTMENTS, LLC 5.93M Mar 31, 2026 8.64% $0.83 0.00%
FMR Inc 5.14M Mar 31, 2026 7.48% $0.00 0.00%
Deep Track Capital, LP 3.33M Jun 30, 2026 4.86% $1.30 0.00%
venBio Select Advisor LLC 1.80M Mar 31, 2026 2.62% $0.25 0.00%
The Toronto-Dominion Bank 1.40M Mar 31, 2026 2.04% $0.03 0.00%
Foresite Capital Management VI LLC 940.49K Jun 30, 2026 1.37% $3.93 198.10%
Jefferies Financial Group Inc 712.30K Mar 31, 2026 1.04% $0.07 0.00%
BlackRock Inc 455.62K Mar 31, 2026 0.66% $0.00 4.88%
UBS Group AG 412.42K Mar 31, 2026 0.60% $0.00 13.49%
Millennium Management LLC 323.40K Jun 30, 2026 0.47% $0.00 -65.52%
BOOTHBAY FUND MANAGEMENT, LLC 282.89K Mar 31, 2026 0.41% $0.05 152.17%
HighVista Strategies LLC 158.77K Jun 30, 2026 0.23% $0.97 -25.53%
Marshall Wace Asset Management Ltd 91.11K Mar 31, 2026 0.13% $0.00 -62.16%
Occam Crest Management L.P. 80.00K Mar 31, 2026 0.12% $0.68 0.00%
AdvisorShares Investments, LLC 71.27K Jun 30, 2026 0.10% $0.23 6.31%
Trexquant Investment LP 69.81K Mar 31, 2026 0.10% $0.01 27.44%
CenterBook Partners LP 69.44K Jun 30, 2026 0.10% $0.09 -67.94%
Citadel Advisors Llc 65.46K Mar 31, 2026 0.10% $0.00 149.31%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 3.00M 4.37% ▲ 1.71% Jul 31, 2026
2 Fidelity Growth Company Fund 1.90M 2.76% ▲ 2.13% Jul 31, 2026
3 Fidelity Growth Company K6 616.54K 0.90% ▲ 1.82% Jul 31, 2026
4 Fidelity Series Growth Company 476.70K 0.69% ▲ 1.88% Jul 31, 2026
5 iShares Biotechnology ETF 365.44K 0.53% ▲ 0.80% Aug 31, 2026
6 Fidelity Select Biotechnology 173.40K 0.25% ▲ 87.46% Jul 31, 2026
7 AdvisorShares Psychedelics ETF 90.07K 0.13% ▲ 0.00% Aug 31, 2026
8 BNY Mellon Sm/Md Cp Gr I 73.13K 0.11% ▲ 0.00% Jul 31, 2026
9 iShares Nasdaq US Biotech ETF USD Acc 56.14K 0.08% ▲ 1.06% Aug 28, 2026
10 iShares MSCI Ireland ETF 52.76K 0.08% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $1.89B
EBITDA: $-71.33M
Book Value: $5.24
Earnings/Share: $-0.98
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -13.02%
ROE (TTM): -18.79%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $1.55B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 68.64M
Shares Float: 32.37M
% Insiders: 24.20%
% Institutions: 71.36%
Short % Float: 11.69%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-335.00K
Gross Profit
subtotal
$-335.00K
SG&A
adjust
$-21.65M
R&D
adjust
$-38.73M
Operating Income
subtotal
$-60.68M
Other / Non-Operating Items
adjust
$12.42M
Net Income
subtotal
$-48.26M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GHRS.US!